Galderma Laboratories has agreed to a $990,000 settlement to resolve a class action lawsuit alleging that certain Differin branded benzoyl peroxide acne treatments were potentially contaminated with benzene, a well known carcinogen. The settlement received preliminary court approval on February 19, 2026, and covers consumers who purchased the affected products in the United States between January 1, 2020, and February 19, 2026.

Which Products Are Covered

Three Differin branded products are included in the settlement:

• Differin Daily Deep Cleanser (5% Benzoyl Peroxide)
• Differin Acne Spot Treatment (10% Benzoyl Peroxide)
• Differin Maximum Strength Acne Foaming Cleanser (10% Benzoyl Peroxide)

The lawsuit, filed as Williams v. Galderma Laboratories, L.P. in the Northern District of Illinois, alleged that Galderma failed to warn consumers that these products may have been contaminated with benzene and misled buyers about the safety of the treatments they were purchasing.

What Affected Consumers Can Claim

Class members who submit…